(Q77366694)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9759552%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

review article

1 reference

title

Therapies aimed at airway inflammation in cystic fibrosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9759552%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

1 reference

M W Konstan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9759552%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

publication date

1 September 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9759552%20AND%20SRC:MED&resulttype=core&format=json

Clinics in Chest Medicine

5 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9759552%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9759552%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9759552%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

page(s)

505-13, vi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9759552%20AND%20SRC:MED&resulttype=core&format=json

Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis.

5 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Effects of pentoxifylline on sputum neutrophil elastase and pulmonary function in patients with cystic fibrosis: preliminary observations

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Protease-antiprotease imbalance in the lungs of children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

1 reference

7 January 2021

Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Interleukin-1 alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Current understanding of the inflammatory process in cystic fibrosis: onset and etiology

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Effect of high-dose ibuprofen in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Aerosol α1 -antitrypsin treatment for cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Cystic fibrosis gene mutation (deltaF508) is associated with an intrinsic abnormality in Ca2+-induced arachidonic acid release by epithelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Vitamin E supplementation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Management of pulmonary disease in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Systemic deficiency of glutathione in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. A longitudinal study of immune complex activity and inflammatory response in sputum sol-phase of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections: influenc

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Plasma vitamin C concentrations in patients with cystic fibrosis: evidence of associations with lung inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Neutrophil elastase/alpha 1-proteinase inhibitor complex levels decrease in plasma of cystic fibrosis patients during long-term oral beta-carotene supplementation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970096-4

7 January 2021

10.1016/S0272-5231(05)70096-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9759552%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

1 reference